Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) will end internally funded development of SkinJect for sporadic nodular basal cell carcinoma and concentrate its clinical spending on Gorlin syndrome, narrowing …
ICYMI: Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma is ending further development of SkinJect for sporadic nodular basal cell carcinoma and concentrating its investment on an FDA-authorized Phase 2b study in Gorlin syndrome, …
Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is making precision oncology its primary development strategy, concentrating capital and clinical resources on the CD228V antibody-drug conjugate while seeking partnerships to …
Medicus Shifts Strategy to Precision Oncology With CD228V Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received FDA authorization to begin an NDA-enabling Phase 2b study of SkinJect in patients with Gorlin Syndrome, advancing the company’s lead program …
FDA Clears Medicus SkinJect Study for Gorlin Syndrome Read More CONSHOHOCKEN, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) agreed Wednesday to pay Pfizer Inc. $27 million for worldwide rights to an early-stage antibody-drug conjugate, taking control of CD228V’s development while …
Medicus Pays $27 Million for Pfizer Cancer Drug Rights Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) appointed Chief Medical Officer Faisal Mehmud as chief executive officer of its UK subsidiary Antev Limited, effective Aug. 30, consolidating leadership as …
Medicus Puts Mehmud at Antev Helm as Drug Program Advances Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has received authorization from the Abu Dhabi Department of Health to begin a Phase 2a clinical trial of its investigational therapy Teverelix …
ICYMI: Medicus Pharma Wins UAE Trial Authorization for Endometriosis Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. received FDA clearance to begin a registrational Phase 2b trial of its SkinJect microneedle patch in patients with Gorlin Syndrome, advancing the treatment toward …
ICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received authorization from Abu Dhabi health regulators to proceed with a Phase 2a trial of Teverelix in women with symptomatic endometriosis, advancing …
Medicus Wins UAE Clearance for Genomics-Guided Drug Trial Read More